ATE206432T1 - A3 -adenosin -rezeptor agonisten - Google Patents

A3 -adenosin -rezeptor agonisten

Info

Publication number
ATE206432T1
ATE206432T1 AT94923445T AT94923445T ATE206432T1 AT E206432 T1 ATE206432 T1 AT E206432T1 AT 94923445 T AT94923445 T AT 94923445T AT 94923445 T AT94923445 T AT 94923445T AT E206432 T1 ATE206432 T1 AT E206432T1
Authority
AT
Austria
Prior art keywords
receptor
adenosine receptor
mammal
uronamide
provides
Prior art date
Application number
AT94923445T
Other languages
English (en)
Inventor
Kenneth A Jacobson
Carola Gallo-Rodriguez
Galen Philip J M Van
Lubitz Dag K J E Von
Heaok Kim Jeong
Seodaemun-Ku College Of P Dong
Original Assignee
Nasa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nasa filed Critical Nasa
Application granted granted Critical
Publication of ATE206432T1 publication Critical patent/ATE206432T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT94923445T 1993-07-13 1994-07-13 A3 -adenosin -rezeptor agonisten ATE206432T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9110993A 1993-07-13 1993-07-13
US16332493A 1993-12-06 1993-12-06
PCT/US1994/007835 WO1995002604A1 (en) 1993-07-13 1994-07-13 A3 adenosine receptor agonists

Publications (1)

Publication Number Publication Date
ATE206432T1 true ATE206432T1 (de) 2001-10-15

Family

ID=26783598

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94923445T ATE206432T1 (de) 1993-07-13 1994-07-13 A3 -adenosin -rezeptor agonisten

Country Status (6)

Country Link
US (1) US5773423A (de)
EP (1) EP0708781B1 (de)
AT (1) ATE206432T1 (de)
AU (1) AU7331094A (de)
DE (1) DE69428536T2 (de)
WO (1) WO1995002604A1 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301000D0 (en) * 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
WO1997037667A1 (en) 1996-04-10 1997-10-16 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of an a1 adenosine receptor agonist to treat cerebral ischaemia
GB9610031D0 (en) * 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
WO1998006855A1 (en) * 1996-08-16 1998-02-19 The Texas A & M University System Compositions and methods for delivery of nucleic acids to hepatocytes
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
JP2002505687A (ja) 1997-06-18 2002-02-19 ディスカバリー セラピューティクス，インコーポレイテッド 脈管再生手順の後の再狭窄を防止するための組成物および方法
US6110902A (en) * 1997-06-23 2000-08-29 Moehler; Hanns Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US20020058669A1 (en) * 1998-06-15 2002-05-16 Herman H. P. M. Van Helden Process for the treatment of organophosphate poisoning
US6495528B1 (en) 1998-06-23 2002-12-17 Smithkline Beecham Corporation 2-(Purin -9-yl)-tetrahydrofuran-3,4-diol derivatives
CA2336967C (en) 1998-07-10 2010-06-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
CO5180581A1 (es) * 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
ATE336492T1 (de) * 2000-01-14 2006-09-15 Us Gov Health & Human Serv Methonocarbacycloalkylanaloga von nucleosiden
US20010051348A1 (en) 2000-01-28 2001-12-13 Lee Chee Wee Novel ligands and methods for preparing same
CA2434906C (en) 2001-01-16 2008-08-19 Can-Fite Biopharma Ltd. Use of an adenosine a3 receptor agonist for inhibition of viral replication
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
EP1241176A1 (de) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purinderivate zur Behandlung von Ischämie
JP2002338593A (ja) 2001-05-22 2002-11-27 Ajinomoto Co Inc β−Ｄ−リボフラノース誘導体又はその光学異性体の製造方法
US6921594B2 (en) * 2001-12-19 2005-07-26 Sud-Chemie Inc. Exhaust treatment and filtration system for molten carbonate fuel cells
US6846988B2 (en) * 2002-01-18 2005-01-25 Adc Telecommunications, Inc. Triaxial connector including cable clamp
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
AU2003282359A1 (en) * 2002-11-19 2004-06-15 Can-Fite Biopharma Ltd. A3ar agonists for the treatment of inflammatory arthritis
CZ294538B6 (cs) * 2002-12-30 2005-01-12 Ústav Experimentální Botaniky Akademie Vědčeské Re Substituční deriváty N6-benzyladenosinu, způsob jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
US20050101560A1 (en) * 2003-11-12 2005-05-12 Can-Fite Biopharma Ltd. Method of treating an individual with methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl] beta-D-ibofuronamide
EP1699459B1 (de) * 2003-12-29 2007-06-06 Can-Fite Biopharma Ltd. Verfahren zur behandlung von multipler sklerose
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
ME01072B (de) 2004-05-26 2012-10-20 Inotek Pharmaceuticals Corp Purinderivate als adenosin a 1 rezeptoragonisten und anwendungsverfahren dafür
US7825102B2 (en) * 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
ES2432113T3 (es) * 2004-07-28 2013-11-29 Can-Fite Biopharma Ltd. Agonistas del receptor de adenosina A3 para el tratamiento de trastornos del ojo seco, incluido el síndrome de Sjogren
KR20070050484A (ko) * 2004-09-09 2007-05-15 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Ａ1 및 ａ3 아데노신 수용체 아고니스트로서의 퓨린 유도체
CA2581132A1 (en) 2004-09-20 2006-03-30 Inotek Pharmaceuticals Corporation Purine 5'-carboxamide derivatives and their use as adenosine receptor agonists
US20080051364A1 (en) * 2004-11-08 2008-02-28 Pninna Fishman Therapeutic Treatment of Accelerated Bone Resorption
US20080070860A1 (en) * 2005-02-04 2008-03-20 Uti Limited Partnership Adenosine Analogs Useful as Anti-Bacterial and Anti Protozoan Agents
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
BRPI0619261A2 (pt) 2005-11-30 2011-09-27 Inotek Pharmaceuticals Corp derivados de purina e métodos de uso desses
JP5339916B2 (ja) * 2005-11-30 2013-11-13 キャン−ファイト・バイオファーマ・リミテッド 骨関節炎の治療におけるａ３アデノシン受容体アゴニストの使用
CN101472926A (zh) * 2006-04-13 2009-07-01 阿斯利康(瑞典)有限公司 硫代黄嘌呤衍生物以及它们作为髓过氧化物酶抑制剂的用途
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
US7897737B2 (en) 2006-12-05 2011-03-01 Lasergen, Inc. 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
US7893227B2 (en) * 2006-12-05 2011-02-22 Lasergen, Inc. 3′-OH unblocked nucleotides and nucleosides base modified with non-cleavable, terminating groups and methods for their use in DNA sequencing
PT2137202T (pt) * 2007-03-14 2017-10-02 Can-Fite Biopharma Ltd Processo para a síntese de ib-meca
WO2009006046A1 (en) 2007-06-29 2009-01-08 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Dendrimer conjugates of agonists and antagonists of the gpcr superfamily
EP2227234B1 (de) * 2007-10-15 2014-05-07 Can-Fite Biopharma Ltd. Verfahren zur herbeiführung einer hepatozytenproliferation und seine anwendungen
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
WO2010014921A2 (en) * 2008-08-01 2010-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
AU2009231978C1 (en) 2008-03-31 2014-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 adenosine receptor- selective agonists
AU2009257369B2 (en) 2008-06-11 2015-03-26 Agilent Technologies, Inc. Nucleotides and nucleosides and methods for their use in DNA sequencing
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
WO2010134067A1 (en) 2009-05-17 2010-11-25 Can-Fite Biopharma Ltd. A3 adenosine receptor agonists for the reduction of intraocular pressure
US9199102B2 (en) 2009-07-21 2015-12-01 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
EP2507241A1 (de) 2009-12-02 2012-10-10 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosin-derivate und dendrimerkonjugate daraus
JP2013516495A (ja) 2010-01-11 2013-05-13 イノテック ファーマシューティカルズ コーポレイション 眼圧を低下させる組合せ、キット、および方法
US20130045943A1 (en) 2010-03-03 2013-02-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of A3ar agonists for the treatment of uveitis
JP2013523739A (ja) 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
WO2011123518A1 (en) 2010-03-31 2011-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
US20130165399A1 (en) 2010-06-18 2013-06-27 Hayashibara Co., Ltd. Therapeutic agent for inflammatory diseases, containing adenosine n1-oxide as an effective ingredient
JP6577165B2 (ja) 2011-01-26 2019-09-18 北京康倍得医▲藥▼技▲術▼▲開▼▲發▼有限公司 リボフラノシルプリン化合物、その調製方法、およびその使用
CN102617680B (zh) * 2011-02-01 2014-04-02 复旦大学 一种双功能抗血小板聚集药物及其用途
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
EP3670523B1 (de) 2011-09-13 2021-08-11 Agilent Technologies, Inc. 3'-oh-unblockierte, schnell photospaltbare endgruppennukleotide und ihre verwendung in nukleinsäuresequenzierungsverfahren
SMT201700377T1 (it) 2012-01-26 2017-09-07 Inotek Pharmaceuticals Corp Polimorfi anidri di (2r,3s,4r,5r)-5-(6-(ciclopentilammino)-9h-purin-9-il)-3,4- diidrossitetraidrofuran-2-il)}metil nitrato e processi di sua preparazione
CN103421067A (zh) * 2012-05-18 2013-12-04 复旦大学 一种双靶点抗血小板聚集药物及其用途
MX378538B (es) 2012-08-09 2025-03-10 Can Fite Biopharma Ltd Ligandos del receptor de adenosina a3 para su uso en el tratamiento de una disfuncion sexual.
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
JP2015172077A (ja) * 2015-06-24 2015-10-01 中国医学科学院葯物研究所 Ｎ６−置換アデノシン誘導体とｎ６−置換アデニン誘導体の鎮静、催眠、抗うつ、抗痙攣、抗てんかん、抗パーキンソン病と認知証予防・治療の用途
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
CN109310695B (zh) * 2016-04-21 2022-04-01 阿斯特罗赛特制药公司 治疗神经和心血管病况的化合物和方法
CN106632333A (zh) * 2016-11-30 2017-05-10 湖州恒远生物化学技术有限公司 一种低成本8‑氯茶碱的制备方法
IL254535A0 (en) 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
CN109666053A (zh) * 2017-10-16 2019-04-23 张家口华健致远生物科技有限公司 一种a3腺苷受体激动剂及其用途
WO2019105388A1 (zh) * 2017-11-29 2019-06-06 苏州科睿思制药有限公司 一种a3腺苷受体激动剂药物的晶型及其制备方法和用途
US11839615B2 (en) 2018-02-09 2023-12-12 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating addiction and related disorders
EP3856741A4 (de) 2018-09-26 2022-06-22 Astrocyte Pharmaceuticals, Inc. Polymorphe verbindungen und verwendungen davon
IL264112A (en) 2019-01-06 2020-07-30 Fishman Pnina An a3 adenosine receptor ligand for use for reducing level of adipocytes
JP2024502068A (ja) * 2020-12-29 2024-01-17 チョーチヤン ビムグリーン ファーマシューティカルズ、リミテッド Ａ３アデノシン受容体アゴニスト及びその調製方法と用途
IT202300014340A1 (it) 2023-07-10 2025-01-10 Consiglio Nazionale Ricerche Trattamento di malattie associate alla disfunzione del gene ocrl.
IT202300020286A1 (it) 2023-10-02 2025-04-02 Procos Spa Processo per la sintesi di piclidenoson a partire dall’adenosina

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6717061A (de) * 1966-12-21 1968-06-24
DE2524284A1 (de) * 1966-12-21 1976-10-28 Boehringer Mannheim Gmbh Adenosin-derivate und verfahren zu ihrer herstellung
US5310731A (en) * 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
US5140015A (en) * 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage

Also Published As

Publication number Publication date
WO1995002604A1 (en) 1995-01-26
DE69428536T2 (de) 2002-06-06
EP0708781A1 (de) 1996-05-01
AU7331094A (en) 1995-02-13
DE69428536D1 (de) 2001-11-08
US5773423A (en) 1998-06-30
EP0708781B1 (de) 2001-10-04

Similar Documents

Publication Publication Date Title
DE69428536D1 (de) A3 -adenosin -rezeptor agonisten
DE69422191D1 (de) A1 adenosin rezeptor agonisten und antagonisten
SE0003984L (sv) Adenosin A3-receptormodulatorer
DE68914929D1 (de) Emulgierte Zusammensetzung.
BR9612324A (pt) "agonistas e antagonistas receptores de adenosina a"
DK330789A (da) Substituerede 1,7-annellerede 1 h-indazoler
DE3887839D1 (de) Trennmittelzusammensetzung.
FI943817A7 (fi) Bisyklo/2.2.2/oktaanijohdannaisia kolestokystokiniinin inhibiittoreina
DE3884605D1 (de) Feuerbestaendige zusammensetzung.
IT8820386A0 (it) Composizioni farmaceutiche orosolubili contenti acetilcisteina.
DE69004256D1 (de) Dihydropyrimidin-antiallergie-mittel.
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
FI910455L (fi) Komposition med foerbaettrad penetration.
DE3852988D1 (de) Propylen-Ethylen-Blockcopolymer Zusammensetzung.
NO943846L (no) Angiotensin II antagonister mot forstyrrelser knyttet til svekket nerveledningshastighet, særlig diabetisk nevropati
FI955260L (fi) Transdermaalisia terapeuttisia systeemejä serotoniiniagonistien antamista varten
FI883673A0 (fi) Farmaceutiska kompositioner.
DK630589A (da) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor-sammensaetning
DK0449175T3 (da) Selektive adenosinreceptormidler
ES2106025T3 (es) Analogos de gangliosidos semisinteticos.
NO985079L (no) Eksplosiv formulering
DE68915203D1 (de) Pharmazeutische Mischungen.
ATE113949T1 (de) Alpha-adrenergische rezeptorantagonisten.
ES2072869T3 (es) Uso de derivados de la 1,4-dihidropiridina en el tratamiento del alcoholismo.
IT8119758A0 (it) Derivati 2'-deossi-3',5'-di-o-alchilcarbonil-5-fluorouri dinici processo per la loro preparazione e agenti antitumorali che contengono i detti derivati.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties